Yescarta: Clinical Trials

11 trials of Yescarta, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 2 active not recruiting, 2 completed, 1 not yet recruiting. 11 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Recruiting 4, Active not recruiting 2, Completed 2, Not yet recruiting 1, Suspended 1, Terminated 1
Phase 13Active not recruiting 1, Not yet recruiting 1, Suspended 1

Follow Yescarta: new trials by email Literature Review of Yescarta trials Research Report on Yescarta

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy
Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Phase 2RecruitingUniversity of Michigan Rogel Cancer Center262026-11-012026-10-23
Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2Not yet recruitingUniversity of Michigan Rogel Cancer Center122026-11-012026-11-12
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Phase 2RecruitingCity of Hope Medical Center562026-02-112026-03-05
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma
Phase 2RecruitingSWOG Cancer Research Network3962023-06-122026-10-15
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy - Diffuse Large B Cell Lymphoma
Phase 2RecruitingH. Lee Moffitt Cancer Center and Research Institute272023-05-192026-09-16
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma
Phase 1 / Phase 2SuspendedMasonic Cancer Center, University of Minnesota302021-06-092026-11-04
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
Acalabrutinib, Axicabtagene Ciloleucel - B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Phase 1 / Phase 2Active not recruitingUniversity of Washington232020-12-022026-06-25
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma
Phase 2CompletedM.D. Anderson Cancer Center222020-07-272025-01-28
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma
Phase 2TerminatedJonsson Comprehensive Cancer Center232020-03-042026-02-27
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Itacitinib, Immune effector cell therapy, Placebo - Cytokine Release Syndrome
Phase 2CompletedIncyte Corporation1122020-02-072024-03-26
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
KYMRIAH, YESCARTA, Fludarabine 30mg/m2 4 doses - Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Phase 2Active not recruitingMasonic Cancer Center, University of Minnesota1502018-12-182026-01-23

Conditions studied

Lymphoma, Large B-Cell, Diffuse (9)  ·  Cytokine Release Syndrome (1)  ·  Disease Progression (1)  ·  Hematologic Neoplasms (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Sponsors

Masonic Cancer Center, University of Minnesota (2)  ·  University of Michigan Rogel Cancer Center (2)  ·  City of Hope Medical Center (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Incyte Corporation (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  M.D. Anderson Cancer Center (1)  ·  SWOG Cancer Research Network (1)  ·  University of Washington (1)

Countries

United States (11)

Top investigators

Ajay Gopal (1)  ·  Brian T Hess (1)  ·  John M Timmerman, MD (1)  ·  Karamjeet S Sandhu (1)  ·  Marcus Geer (1)  ·  Michael Jain, MD, PhD (1)  ·  Monalisa Ghosh (1)  ·  Paolo Strati (1)  ·  Peter Langmuir, MD (1)  ·  Veronika Bachanova, MD (1)  ·  Veronika Bachanova, MD, PhD (1)

Results publications

PMID 32998963, PMID 38022532, PMID 40090005

NIH funding

P30CA033572 (1), U10CA180888 (1)